Some way to go before decision on Biogen Alzheimer s drug, says UnitedHealth
biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.
UnitedHealth Escalates Partnerships To Address Health Inequity
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Emma Walmsley must win over staff in battle to make GSK great again
telegraph.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from telegraph.co.uk Daily Mail and Mail on Sunday newspapers.
5 Min Read
(Reuters) -Biogen Inc’s Alzheimer’s drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on Thursday with some large hospitals declining to use it and health insurers delaying a decision while awaiting coverage terms from Medicare.
FILE PHOTO: Aduhelm, Biogen s controversial recently approved drug for early Alzheimer s disease, is seen at Butler Hospital, one of the clinical research sites in Providence, Rhode Island, U.S. June 16, 2021. Jessica Rinaldi/Pool via REUTERS
An influential panel of medical experts also voted unanimously that there is no evidence that the drug, Aduhelm, provides a net health benefit to patients.